View Post

FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer

In In The News by Barbara Jacoby

From: .onclive.com The FDA has granted fast track designation to ETX-19477 for the treatment of adult patients with BRCA-mutated, hormone receptor (HR)–positive, HER2-negative unresectable or metastatic breast cancer.1 ETX-19477 is an oral, potent, and selective inhibitor of poly(ADP-ribose) glycohydrolase (PARG), is being evaluated as monotherapy in the phase 1/2 ERADIC8 trial (NCT06395519), which is enrolling phase 2 cohorts of patients …